Prevalence of and change in the prescription of methylphenidate in Israel over a 2-year period

CNS Drugs

Volumn 17, Issue 12, 2003, Pages 915-919

  Fogelman, Yacov ^a,d   Vinker, Shlomo ^b   Guy, Nir ^c   Kahan, Ernesto ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HAEMEK MEDICAL CENTER   (Israel)

^d NONE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CULTURAL ANTHROPOLOGY; DEVELOPING COUNTRY; DRUG MONITORING; ECONOMIC ASPECT; FEMALE; HEALTH SURVEY; HUMAN; INFANT; ISRAEL; MAJOR CLINICAL STUDY; MALE; NEWBORN; PHYSICIAN; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RACE DIFFERENCE; STATISTICAL ANALYSIS;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; ISRAEL; MALE; METHYLPHENIDATE; PRESCRIPTIONS, DRUG; PREVALENCE;

EID: 0141639815     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200317120-00005     Document Type: Article

References (29)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
2. Fogelman Y, Kahan E. Methylphenidate use for attention deficit hyperactivity disorder in northern Israel: a controversial issue. Isr Med Assoc J 2001 Dec 3; 3 (12): 925-7
3. Jensen PS, Hinshaw SP, Swanson JM, et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr 2001 Feb; 22 (1): 60-73
4. Jensen PS, Kettle L, Roper MT, et al. Are stimulants over-prescribed? Treatment of ADHD in four US communities. J Am Acad Child Adolesc Psychiatry 1999 Jul; 38 (7): 797-804
5. Shatin D, Drinkard CR. Ambulatory use of psychotropics by employer-insured children and adolescents in a national managed care organization. Ambul Pediatr 2002 Mar-Apr; 2 (2): 111-9
6. Zito JM, Safer DJ, DosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 2003 Jan; 157 (1): 17-25
7. Martin A, Van Hoof T, Stubbe D, et al. Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid Managed Care. Psychiatr Serv 2003 Jan; 54 (1): 72-7
8. Cox ER, Motheral BR, Henderson RR, et al. Geographic variation in the prevalence of stimulant medication use among children 5 to 14 years old: results from a commercially insured US sample. Pediatrics 2003 Feb; 111 (2): 237-43
9. Robison LM, Skaer TL, Sclar DA, et al. Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants. CNS Drugs 2002; 16 (2): 129-37
10. Safer DJ, Krager JM. A survey of medication treatment for hyperactive/inattentive students. JAMA 1988; 260: 2256-8
11. Olfson M, Marcus SC, Weissman MM, et al. National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry 2002 May; 41 (5): 514-21
12. Rushton JL, Whitmire JT. Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends 1992 to 1998. Arch Pediatr Adolesc Med 2001; 155: 560-5
13. Romano E, Baillargeon RH, Wu HX, et al. Prevalence of methylphenidate use and change over a two-year period: a nationwide study of 2- to 11-year-old Canadian children. J Pediatr 2002 Jul; 141 (1): 71-5
14. Miller AR, Lalonde CE, McGrail KM, et al. Prescription of methylphenidate to children and youth, 1990-1996. CMAJ 2001 Nov 27; 65 (11): 489-94
15. Berbatis CG, Sunderland VB, Bulsara M. Licit psychostimulant consumption in Australia, 1984-2000: international and jurisdictional comparison. Med J Aust 2002 Nov 18; 177 (10): 539-43
16. Sawyer MG, Rey JM, Graetz BW, et al. Use of medication by young people with attention-deficit/hyperactivity disorder. Med J Aust 2002 Jul 1; 177 (1): 21-5
17. Zwi M, Ramchandani P, Joughin C. Evidence and belief in ADHD. BMJ 2000; 321: 975-6
18. Schirm E, Tobi H, Zito JM, et al. Psychotropic medication in children: a study from the Netherlands. Pediatrics 2001 Aug; 108 (2): E25
19. Madsen H, Andersen M, Hallas J. Drug prescribing among Danish children: a population-based study. Eur J Clin Pharmacol 2001 May; 57 (2): 159-65
20. Swanson M, Sergeant JA, Taylor E, et al. Attention deficit-hyperactivity disorder and hyperkinetic disorder. Lancet 1998; 351: 429-33
21. Taylor E, Sandberg S, Thorley G, et al. The epidemiology of childhood hyperactivity. London: Oxford University Press, 1991
22. Elliger TJ. Methylphenidat-aktuelle verordnungzahlen. Z Kinder Jugendpsychiatr 1991; 19: 268-70
23. Rappley MD, Gardiner JC, Jetton JR, et al. The use of methylphenidate in Michigan. Arch Pediatr Adolesc Med 1995; 149: 675-9
24. Kwasman A, Tinsley BJ, Lepper HS. Pediatricians' knowledge and attitude concerning diagnosis and treatment of attention deficit and hyperactivity disorders: a national survey approach. Arch Pediatr Adolesc Med 1995; 149: 1211-6
25. Wolraich ML, Lindgren S, Stromquist A. Stimulant medication use by primary care physicians in the treatment of attention deficit-hyperactivity disorder. Pediatrics 1990; 86: 95-101
26. Cowart VS. The Ritalin controversy: what's made this drug's opponents hyperactive? JAMA 1988; 259: 2521-3
27. Zito JM, Safer DJ, DosReis S, et al. Methylphenidate patterns among Medicaid youths. Psychopharmacol Bull 1997; 33: 143-7
28. Herman J, Epstein L. Benign prostatic hypertrophy: a review from family practice. Fam Syst Med 1990; 8: 365-70
29. Chassin MR, Kosecoff J, Park RE, et al. Does inappropriate use explain geographic variation in the use of health care services? JAMA 1987; 258: 2533-7